---
document_datetime: 2025-12-29 11:23:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lyfnua.html
document_name: lyfnua.html
version: success
processing_time: 0.1180533
conversion_datetime: 2025-12-30 09:22:26.57904
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lyfnua

[RSS](/en/individual-human-medicine.xml/67712)

##### Authorised

This medicine is authorised for use in the European Union

gefapixant Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lyfnua](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-81725)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lyfnua is a medicine used to treat adults with chronic (long-term) cough which is unexplained or for which other treatments have not worked.

The medicine contains the active substance gefapixant.

Expand section

Collapse section

## How is Lyfnua used?

In response to inflammation or airway irritation, cells within the lining of the airways produce high levels of a substance called ATP. ATP attaches to specific receptors (targets) on nerve cells in the airways, which stimulates the nerves and triggers the urge to cough. The active substance in Lyfnua, gefapixant, blocks these receptors and keeps the nerves from triggering the cough reflex.

## What benefits of Lyfnua have been shown in studies?

The benefits of Lyfnua were investigated in two main studies involving 1,360 adults with chronic cough, who were given Lyfnua or placebo (a dummy treatment). Lyfnua was shown to be more effective than placebo at lowering the average number of times patients coughed per hour, measured over a 24-hour period. In the first study, after 12 weeks of treatment, the average number of coughs per hour in patients given Lyfnua went from 18.2 to 7.1 (a reduction of 61%) compared with a decrease from 22.8 to 10.3 (a reduction of 55%) in patients given placebo. In the second study, after 24 weeks of treatment, the average number of coughs per hour went from 18.6 to 6.8 (a reduction of 63%) in patients given Lyfnua compared with a decrease from 19.5 to 8.3 (a reduction of 57%) in patients given placebo.

## What are the risks associated with Lyfnua?

For the full list of side effects and restrictions with Lyfnua, see the package leaflet.

The most common side effects with Lyfnua (which may affect more than 1 in 10 people) include taste disorders: dysgeusia (changes in the sense of taste), ageusia (loss of sense of taste) and hypogeusia (reduced sense of taste).

## Why is Lyfnua authorised in the EU?

Lyfnua showed a modest effect in terms of reducing the number of daily coughs in patients with chronic cough. Side effects with Lyfnua are considered manageable; the most common side effects concerned taste disorders and these generally resolved once patients stopped treatment. The European Medicines Agency therefore decided that Lyfnua's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lyfnua?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lyfnua have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lyfnua are continuously monitored. Suspected side effects reported with Lyfnua are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lyfnua

Lyfnua received a marketing authorisation valid throughout the EU on 15 September 2023.

Lyfnua - EPAR - Medicine overview

Reference Number: EMA/342744/2023

English (EN) (98.47 KB - PDF)

**First published:** 29/09/2023

[View](/en/documents/overview/lyfnua-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-844)

български (BG) (120.53 KB - PDF)

**First published:**

29/09/2023

[View](/bg/documents/overview/lyfnua-epar-medicine-overview_bg.pdf)

español (ES) (98.77 KB - PDF)

**First published:**

29/09/2023

[View](/es/documents/overview/lyfnua-epar-medicine-overview_es.pdf)

čeština (CS) (116.64 KB - PDF)

**First published:**

29/09/2023

[View](/cs/documents/overview/lyfnua-epar-medicine-overview_cs.pdf)

dansk (DA) (98.49 KB - PDF)

**First published:**

29/09/2023

[View](/da/documents/overview/lyfnua-epar-medicine-overview_da.pdf)

Deutsch (DE) (98.91 KB - PDF)

**First published:**

29/09/2023

[View](/de/documents/overview/lyfnua-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.96 KB - PDF)

**First published:**

29/09/2023

[View](/et/documents/overview/lyfnua-epar-medicine-overview_et.pdf)

ελληνικά (EL) (120.22 KB - PDF)

**First published:**

29/09/2023

[View](/el/documents/overview/lyfnua-epar-medicine-overview_el.pdf)

français (FR) (99.13 KB - PDF)

**First published:**

29/09/2023

[View](/fr/documents/overview/lyfnua-epar-medicine-overview_fr.pdf)

hrvatski (HR) (112.35 KB - PDF)

**First published:**

29/09/2023

[View](/hr/documents/overview/lyfnua-epar-medicine-overview_hr.pdf)

italiano (IT) (98.57 KB - PDF)

**First published:**

29/09/2023

[View](/it/documents/overview/lyfnua-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (118.34 KB - PDF)

**First published:**

29/09/2023

[View](/lv/documents/overview/lyfnua-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (116.06 KB - PDF)

**First published:**

29/09/2023

[View](/lt/documents/overview/lyfnua-epar-medicine-overview_lt.pdf)

magyar (HU) (113.5 KB - PDF)

**First published:**

29/09/2023

[View](/hu/documents/overview/lyfnua-epar-medicine-overview_hu.pdf)

Malti (MT) (117.19 KB - PDF)

**First published:**

29/09/2023

[View](/mt/documents/overview/lyfnua-epar-medicine-overview_mt.pdf)

Nederlands (NL) (98.99 KB - PDF)

**First published:**

29/09/2023

[View](/nl/documents/overview/lyfnua-epar-medicine-overview_nl.pdf)

polski (PL) (117.09 KB - PDF)

**First published:**

29/09/2023

[View](/pl/documents/overview/lyfnua-epar-medicine-overview_pl.pdf)

português (PT) (99 KB - PDF)

**First published:**

29/09/2023

[View](/pt/documents/overview/lyfnua-epar-medicine-overview_pt.pdf)

română (RO) (114.9 KB - PDF)

**First published:**

29/09/2023

[View](/ro/documents/overview/lyfnua-epar-medicine-overview_ro.pdf)

slovenčina (SK) (115.18 KB - PDF)

**First published:**

29/09/2023

[View](/sk/documents/overview/lyfnua-epar-medicine-overview_sk.pdf)

slovenščina (SL) (111.32 KB - PDF)

**First published:**

29/09/2023

[View](/sl/documents/overview/lyfnua-epar-medicine-overview_sl.pdf)

Suomi (FI) (98.26 KB - PDF)

**First published:**

29/09/2023

[View](/fi/documents/overview/lyfnua-epar-medicine-overview_fi.pdf)

svenska (SV) (98.21 KB - PDF)

**First published:**

29/09/2023

[View](/sv/documents/overview/lyfnua-epar-medicine-overview_sv.pdf)

Lyfnua : EPAR - Risk management plan

English (EN) (380.77 KB - PDF)

**First published:** 29/09/2023

[View](/en/documents/rmp/lyfnua-epar-risk-management-plan_en.pdf)

## Product information

Lyfnua : EPAR - Product information

English (EN) (293.11 KB - PDF)

**First published:** 29/09/2023

**Last updated:** 08/12/2025

[View](/en/documents/product-information/lyfnua-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-183)

български (BG) (298.85 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/bg/documents/product-information/lyfnua-epar-product-information_bg.pdf)

español (ES) (324.07 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/es/documents/product-information/lyfnua-epar-product-information_es.pdf)

čeština (CS) (317.81 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/cs/documents/product-information/lyfnua-epar-product-information_cs.pdf)

dansk (DA) (312.24 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/da/documents/product-information/lyfnua-epar-product-information_da.pdf)

Deutsch (DE) (323.66 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/de/documents/product-information/lyfnua-epar-product-information_de.pdf)

eesti keel (ET) (295.21 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/et/documents/product-information/lyfnua-epar-product-information_et.pdf)

ελληνικά (EL) (353.22 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/el/documents/product-information/lyfnua-epar-product-information_el.pdf)

français (FR) (351.87 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/fr/documents/product-information/lyfnua-epar-product-information_fr.pdf)

hrvatski (HR) (355.9 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/hr/documents/product-information/lyfnua-epar-product-information_hr.pdf)

íslenska (IS) (302.39 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/is/documents/product-information/lyfnua-epar-product-information_is.pdf)

italiano (IT) (348.21 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/it/documents/product-information/lyfnua-epar-product-information_it.pdf)

latviešu valoda (LV) (375.23 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/lv/documents/product-information/lyfnua-epar-product-information_lv.pdf)

lietuvių kalba (LT) (321.68 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/lt/documents/product-information/lyfnua-epar-product-information_lt.pdf)

magyar (HU) (359.88 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/hu/documents/product-information/lyfnua-epar-product-information_hu.pdf)

Malti (MT) (325.42 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/mt/documents/product-information/lyfnua-epar-product-information_mt.pdf)

Nederlands (NL) (330.42 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/nl/documents/product-information/lyfnua-epar-product-information_nl.pdf)

norsk (NO) (304.96 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/no/documents/product-information/lyfnua-epar-product-information_no.pdf)

polski (PL) (337.49 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/pl/documents/product-information/lyfnua-epar-product-information_pl.pdf)

português (PT) (328.6 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/pt/documents/product-information/lyfnua-epar-product-information_pt.pdf)

română (RO) (330.62 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/ro/documents/product-information/lyfnua-epar-product-information_ro.pdf)

slovenčina (SK) (381.17 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/sk/documents/product-information/lyfnua-epar-product-information_sk.pdf)

slovenščina (SL) (316.55 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/sl/documents/product-information/lyfnua-epar-product-information_sl.pdf)

Suomi (FI) (304.53 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/fi/documents/product-information/lyfnua-epar-product-information_fi.pdf)

svenska (SV) (316.27 KB - PDF)

**First published:**

29/09/2023

**Last updated:**

08/12/2025

[View](/sv/documents/product-information/lyfnua-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000315549 05/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lyfnua : EPAR - All authorised presentations

English (EN) (16.86 KB - PDF)

**First published:** 29/09/2023

[View](/en/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-338)

български (BG) (23.39 KB - PDF)

**First published:**

29/09/2023

[View](/bg/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.51 KB - PDF)

**First published:**

29/09/2023

[View](/es/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_es.pdf)

čeština (CS) (22.22 KB - PDF)

**First published:**

29/09/2023

[View](/cs/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.96 KB - PDF)

**First published:**

29/09/2023

[View](/da/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.42 KB - PDF)

**First published:**

29/09/2023

[View](/de/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.63 KB - PDF)

**First published:**

29/09/2023

[View](/et/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (22.96 KB - PDF)

**First published:**

29/09/2023

[View](/el/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_el.pdf)

français (FR) (20.22 KB - PDF)

**First published:**

29/09/2023

[View](/fr/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.73 KB - PDF)

**First published:**

29/09/2023

[View](/hr/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.03 KB - PDF)

**First published:**

29/09/2023

[View](/is/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.2 KB - PDF)

**First published:**

29/09/2023

[View](/it/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.12 KB - PDF)

**First published:**

29/09/2023

[View](/lv/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (24.75 KB - PDF)

**First published:**

29/09/2023

[View](/lt/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.08 KB - PDF)

**First published:**

29/09/2023

[View](/hu/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (24.4 KB - PDF)

**First published:**

29/09/2023

[View](/mt/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.96 KB - PDF)

**First published:**

29/09/2023

[View](/nl/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.58 KB - PDF)

**First published:**

29/09/2023

[View](/no/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_no.pdf)

polski (PL) (21.24 KB - PDF)

**First published:**

29/09/2023

[View](/pl/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.94 KB - PDF)

**First published:**

29/09/2023

[View](/pt/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_pt.pdf)

română (RO) (22.59 KB - PDF)

**First published:**

29/09/2023

[View](/ro/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (22.68 KB - PDF)

**First published:**

29/09/2023

[View](/sk/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.85 KB - PDF)

**First published:**

29/09/2023

[View](/sl/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.96 KB - PDF)

**First published:**

29/09/2023

[View](/fi/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.64 KB - PDF)

**First published:**

29/09/2023

[View](/sv/documents/all-authorised-presentations/lyfnua-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lyfnua Active substance gefapixant International non-proprietary name (INN) or common name gefapixant Therapeutic area (MeSH) Cough Anatomical therapeutic chemical (ATC) code R05DB29

### Pharmacotherapeutic group

Cough and cold preparations

### Therapeutic indication

Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

## Authorisation details

EMA product number EMEA/H/C/005476

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 20/07/2023 Marketing authorisation issued 15/09/2023 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lyfnua : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (101.93 KB - PDF)

**First published:** 28/05/2025

[View](/en/documents/procedural-steps-after/lyfnua-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Lyfnua : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.67 KB - PDF)

**First published:** 14/05/2025

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/lyfnua-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Lyfnua : EPAR - Public assessment report

Adopted

Reference Number: EMA/357321/2023 Corr.1

English (EN) (5.79 MB - PDF)

**First published:** 29/09/2023

**Last updated:** 10/10/2023

[View](/en/documents/assessment-report/lyfnua-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lyfnua

Adopted

Reference Number: EMA/CHMP/322106/2023

English (EN) (92.63 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lyfnua_en.pdf)

#### News on Lyfnua

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Lyfnua : EPAR - Product information - tracked changes

English (EN) (227.78 KB - DOCX)

**First published:** 08/12/2025

[View](/en/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_en.docx-0)

[Other languages (24)](#file-language-dropdown-715)

български (BG) (202.85 KB - DOCX)

**First published:**

08/12/2025

[View](/bg/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_bg.docx)

español (ES) (173.87 KB - DOCX)

**First published:**

08/12/2025

[View](/es/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_es.docx)

čeština (CS) (179.49 KB - DOCX)

**First published:**

08/12/2025

[View](/cs/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (169.19 KB - DOCX)

**First published:**

08/12/2025

[View](/da/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (163.97 KB - DOCX)

**First published:**

08/12/2025

[View](/de/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (131.52 KB - DOCX)

**First published:**

08/12/2025

[View](/et/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (223.05 KB - DOCX)

**First published:**

08/12/2025

[View](/el/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_el.docx)

français (FR) (182.57 KB - DOCX)

**First published:**

08/12/2025

[View](/fr/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (177.35 KB - DOCX)

**First published:**

08/12/2025

[View](/hr/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (267.94 KB - DOCX)

**First published:**

08/12/2025

[View](/is/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_is.docx)

italiano (IT) (247.2 KB - DOCX)

**First published:**

08/12/2025

[View](/it/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (214.98 KB - DOCX)

**First published:**

08/12/2025

[View](/lv/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (161.05 KB - DOCX)

**First published:**

08/12/2025

[View](/lt/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (261.91 KB - DOCX)

**First published:**

08/12/2025

[View](/hu/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (147.25 KB - DOCX)

**First published:**

08/12/2025

[View](/mt/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (251.8 KB - DOCX)

**First published:**

08/12/2025

[View](/nl/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (210.34 KB - DOCX)

**First published:**

08/12/2025

[View](/no/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_no.docx)

polski (PL) (187.26 KB - DOCX)

**First published:**

08/12/2025

[View](/pl/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_pl.docx)

português (PT) (177.07 KB - DOCX)

**First published:**

08/12/2025

[View](/pt/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_pt.docx)

română (RO) (172.48 KB - DOCX)

**First published:**

08/12/2025

[View](/ro/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (176.38 KB - DOCX)

**First published:**

08/12/2025

[View](/sk/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (149.41 KB - DOCX)

**First published:**

08/12/2025

[View](/sl/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (148.44 KB - DOCX)

**First published:**

08/12/2025

[View](/fi/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (225.49 KB - DOCX)

**First published:**

08/12/2025

[View](/sv/documents/product-information-tracked-changes/lyfnua-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 08/12/2025

## Share this page

[Back to top](#main-content)